The treatment of systemic sclerosis (SSc) represents a great clinical challenge because of the complex disease pathogenesis including vascular, fibrotic, and immune T- and B-lymphocyte-mediated alterations. Therefore, SSc should be treated by combined or sequential therapies according to prevalent clinico-pathogenetic phenotypes. Some preliminary data suggest that rituximab (RTX) may downregulate the B-cell over expression and correlated immunological abnormalities.
|Titolo:||Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature|
|Data di pubblicazione:||2015|
|Appare nelle tipologie:||1.1 Articolo in rivista|